Show simple item record

dc.contributor.authorTashkin, DP
dc.contributor.authorWang, HJ
dc.contributor.authorHalpin, D
dc.contributor.authorKleerup, EC
dc.contributor.authorConnett, J
dc.contributor.authorLi, N
dc.contributor.authorElashoff, R
dc.date.accessioned2021-07-22T07:48:54Z
dc.date.issued2012-08-15
dc.description.abstractBackground: The impact of interventions on the progressive course of COPD is currently assessed by the slope of the annual decline in FEV 1 determined from serial measurements of the post-, in preference to the pre-, bronchodilator FEV 1. We therefore compared the yearly slope and the variability of the slope of the pre- versus the post-bronchodilator FEV 1 in men and women with mild to moderate COPD who participated in the 5-year Lung Health Study (LHS).Methods: Data were analyzed from 4484 of the 5887 LHS participants who had measurements of pre- and post-bronchodilator FEV 1 at baseline (screening visit 2) and all five annual visits. The annual rate of decline in FEV 1 (±SE) measured pre- and post-bronchodilator from the first to the fifth annual visit was estimated separately using a random coefficient model adjusted for relevant covariates. Analyses were performed separately within each of the three randomized intervention groups. In addition, individual rates of decline in pre- and post-bronchodilator FEV 1 were also determined for each participant. Furthermore, sample sizes were estimated for determining the significance of differences in slopes of decline between different interventions using pre- versus post-bronchodilator measurements.Results: Within each intervention group, mean adjusted and unadjusted slope estimates were slightly higher for the pre- than the post-bronchodilator FEV 1 (range of differences 2.6-5.2 ml/yr) and the standard errors around these estimates were only minimally higher for the pre- versus the post-bronchodilator FEV 1 (range 0.05-0.11 ml/yr). Conversely, the standard deviations of the mean FEV 1 determined at each annual visit were consistently slightly higher (range of differences 0.011 to 0.035 L) for the post- compared to the pre-bronchodilator FEV 1. Within each group, the proportion of individual participants with a statistically significant slope was similar (varying by only 1.4 to 2.7%) comparing the estimates from the pre- versus the post-bronchodilator FEV 1. However, sample size estimates were slightly higher when the pre- compared to the post-bronchodilator value was used to determine the significance of specified differences in slopes between interventions.Conclusion: Serial measurements of the pre-bronchodilator FEV 1 are generally sufficient for comparing the impact of different interventions on the annual rate of change in FEV 1. © 2012 Tashkin et al.; licensee BioMed Central Ltd.en_GB
dc.identifier.citationVol. 13, article 70en_GB
dc.identifier.doi10.1186/1465-9921-13-70
dc.identifier.urihttp://hdl.handle.net/10871/126500
dc.language.isoenen_GB
dc.publisherBMCen_GB
dc.rights© 2012 Tashkin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_GB
dc.subjectFEV1 declineen_GB
dc.subjectChronic obstructive pulmonary disease (COPD)en_GB
dc.subjectLung health studyen_GB
dc.subjectPre-bronchodilatoren_GB
dc.subjectPost-bronchodilatoren_GB
dc.titleComparison of the variability of the annual rates of change in FEV 1 determined from serial measurements of the pre- versus post-bronchodilator FEV 1 over 5 years in mild to moderate COPD: Results of the lung health studyen_GB
dc.typeArticleen_GB
dc.date.available2021-07-22T07:48:54Z
dc.identifier.issn1465-9921
dc.descriptionThis is the final published version, available from BMC via the DOI in this record.en_GB
dc.identifier.journalRespiratory Researchen_GB
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_GB
pubs.euro-pubmed-idMED:22894725
dcterms.dateAccepted2012
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2012-08-15
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-07-22T07:44:03Z
refterms.versionFCDVoR
refterms.dateFOA2021-07-22T07:49:26Z
refterms.panelUnspecifieden_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2012 Tashkin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's licence is described as © 2012 Tashkin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.